STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

STAT PlusBiotech FDA approves Orca Bio’s T cell therapy for blood cancer patients Treatment is an alternative approach to traditional matched-donor stem cell transplants Manage alerts for this article Email this article Share this article By Adam FeuersteinJuly 1, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The Food and Drug Administration on Tuesday approved a personalized T-cell therapy from Orca Bio, a private biotech company, that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants. The Orca therapy, called Tregzi, represents an alternative approach to traditional matched-donor stem cell transplantation that can be curative for certain patients with blood cancers, but also carries a high risk of chronic graft-versus-host disease and other long-term complications. Advertisement “This is going to be a really important option for leukemia patients,” said Nate Fernhoff, Orca’s CEO, in an interview with STAT. “Historically, the choice for a stem cell transplant carried a trade off — risks and complications that patients had to accept as part of treatment in search of a cure. With Tregzi’s approval, we hope to show that we can break that trade off, and that we can improve survival free from graft-versus-host disease.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Biotech July 1, 2026 STAT Plus: The biotech scorecard for the third quarter: 15 stock-moving events to watch Biotech June 30, 2026 STAT Plus: AI company Anthropic announces it will begin developing drugs of its own Advertisement Biotech June 30, 2026 STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry The Readout June 30, 2026 STAT Plus: Investors double down on Bain-backed startup Health Tech Newsletter June 30, 2026 STAT Plus: FDA digital leader hints at coming AI policy updates Subscriber Picks